Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
Crystal financial tombstone celebrating Series B financing for Nuvig Therapeutics. The immune drug developer is based in Menlo Park, California. (24ALJ345)
Laboratory-themed crystal financial tombstone commemorating a capital raise by Sartorius Stedim Biotech. The biopharmaceutical company is based in Aubagne, France. (SO24LJW040)
Capsule-themed custom crystal commemoratng the first patient dosed stage in the development of ACR-2316. The cancer treatment was developed by Acrivon Therapeutics, a Watertown, Massachusetts-based biopharmaceutical company. (24AKL397)
Custom Lucite recognizing advances in the automated production of insulin secreting islet cells. (24AKL100)
Crystal financial tombstone celebrating the initial public offering of Emcure Pharmacuticals on the Bombay Stock Exchange and National Stock Exchange. The Pune, India-based drugmaker focuses on women’s healthcare. (24AKL301)
Custom crystal deal toy celebrating Series D funding for SkyCell. The Zug, Switzerland-based company provides temperature-controlled smart air freight containers for shipping pharmaceutical goods, including vaccines. (24LNL090)
Custom deal toy marking the acquisition of Knight Optical, a UK-based manufacturer and developer of optical components. (24AZH154)
Crystal financial tombstone, featuring frosted text, recognizing the acquisition of Neuro Alert. The White Plains, New York-based healthcare company provides neurophysiological monitoring and documentation services. (24AZH133)
